Evidence map›Paper›PMID 42458006›Full record

ArticleAnnals of hematology2026

Peripheral blood CD8 + T-cell count at diagnosis predicts prognosis in R-CHOP-treated diffuse large B-cell lymphoma patients.

Fang Chen, Ping Liu, Jiajia Zhao, Demin Wang, Haifeng Zhen, Juan Jin, Zhi Chao, Dan Zhou, Lu Zhang, Wei Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fang Chen *Central Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China.
Ping Liu *Central Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China.
Jiajia ZhaoCentral Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China.
Demin WangLu'an Maternal and Child Health Hospital, Lu'an, 237006, China.
Haifeng ZhenCentral Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China.
Juan JinCentral Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China.
Zhi ChaoCentral Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China.
Dan ZhouCentral Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China.
Lu ZhangCentral Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China.
Wei ChenCentral Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China.
Zimian LuoCentral Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China. 1840059465@qq.com.
Zhongjun HuoCentral Hospital of Xiangtan, No. 120, Heping Raod, Xiangtan, 411100, China. huozj0102@163.com.

Funding

Health Research Topics of Hunan Provincial Health Commission 20232585
6 · The paper itself

Abstract

While the prognostic significance of peripheral blood (PB) lymphocyte counts in diffuse large B-cell lymphoma (DLBCL) patients treated with Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Prednisone (R-CHOP) is established, the specific role of CD8+ T-cell counts (CD8c) remains unclear. Methods: This retrospective study analyzed 315 newly diagnosed DLBCL patients treated at Central Hospital of Xiangtan from January 2018 to September 2023. We evaluated the prognostic significance of initial CD8c and other clinical parameters using univariate and multivariate survival analyses to identify independent predictors of outcome. An optimal CD8c cut-off value of 264.5×10

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCD8-Positive T-LymphocytesLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overCyclophosphamideDoxorubicinFemaleHumansLymphocyte CountMaleMiddle AgedPrednisonePrognosisRetrospective StudiesCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineCD8 + T-cell countDiffuse large B-cell lymphomaPrognostic factorR-CHOP therapySurvival analysis

Identifiers

PMID42458006
PMCPMC13654882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.